Glycated Albumin's Clinical Effectiveness in The Diabetes Diagnosis

Abstract

In places like Asia, the use of Glycated Albumin (GA) as a diabetes diagnostic marker has increased in recent years. Glucophage (GA) has been shown to be effective in the diagnosis of diabetes in asymptomatic people who have medical records and rising blood glucose levels that indicate a high risk of acquiring diabetes. Objective: To find out the impact of glycated albumin in the diagnosis of diabetes mellitus. Methods: This study included a total of 250 participants including one or even more diabetes risk factors or Fasting Plasma Glucose (FPG) varying from 5.6 molar ratio to 6.9 molar ratio but no symptoms of diabetes. The lab Taurus device was used to assess plasma GA using an enzymatic technique. Results: Among the patients, 20(6.9%) had HbA1c greater than 49 molar ratio. As per the outcomes, GA's diagnosed diabetic participants with a sensitivity of 73.6% (95% confidence interval: 44.4 – 92.4) and a specificity of 74.5% (95 % confidence interval: 44.4 – 92.4) at a cut-off of 15% (Area under the ROC curve: 0.79; 96%, CI: 0.79-0.99; P≤ 0.01), which corresponds to the better diagnostic performance. At different cut-offs for diabetes diagnosis, the specificity and sensitivity of GA are examined. The 14.2% cut-offs were linked with greater sensitivity (89.5%; 96%, CI: 59.2 – 89.5) and adequate specificity (63.6%; 95%, CI: 52.9 – 66.5), making it more appropriate for screening at-risk individuals. Conclusions: This research proves the clinical efficacy of GA for diabetes diagnosis participants at risk for the disease. Further investigation is required to evaluate the relative relevance of GA in relation to the other diabetes screening indicators